ES3033965T3 - Oral composition for delivery of drugs and other substances - Google Patents

Oral composition for delivery of drugs and other substances

Info

Publication number
ES3033965T3
ES3033965T3 ES15832041T ES15832041T ES3033965T3 ES 3033965 T3 ES3033965 T3 ES 3033965T3 ES 15832041 T ES15832041 T ES 15832041T ES 15832041 T ES15832041 T ES 15832041T ES 3033965 T3 ES3033965 T3 ES 3033965T3
Authority
ES
Spain
Prior art keywords
composition
general formula
monoglyceride
agent
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15832041T
Other languages
English (en)
Spanish (es)
Inventor
Walter Shaw
Stephen W Burgess
Shengrong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanti Polar Lipids LLC
Original Assignee
Avanti Polar Lipids LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanti Polar Lipids LLC filed Critical Avanti Polar Lipids LLC
Application granted granted Critical
Publication of ES3033965T3 publication Critical patent/ES3033965T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15832041T 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances Active ES3033965T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462035393P 2014-08-09 2014-08-09
PCT/US2015/044501 WO2016025401A1 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Publications (1)

Publication Number Publication Date
ES3033965T3 true ES3033965T3 (en) 2025-08-11

Family

ID=55304531

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15832041T Active ES3033965T3 (en) 2014-08-09 2015-08-10 Oral composition for delivery of drugs and other substances

Country Status (11)

Country Link
US (3) US9872908B2 (enExample)
EP (1) EP3177279B1 (enExample)
JP (1) JP6759203B2 (enExample)
KR (2) KR102507657B1 (enExample)
CN (1) CN107072967B (enExample)
AU (1) AU2015301952B2 (enExample)
CA (1) CA2956960C (enExample)
DK (1) DK3177279T3 (enExample)
ES (1) ES3033965T3 (enExample)
IL (1) IL250394B (enExample)
WO (1) WO2016025401A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514755A1 (fr) 1981-10-21 1983-04-22 Rhone Poulenc Chim Base Procede de preparation de l'anhydride acetique
ZA831053B (en) * 1982-02-17 1985-03-27 Ciba Geigy Ag Lipids in aqueous phase
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
IE59067B1 (en) * 1985-04-02 1993-12-15 Yesair David W Composition for delivery of orally administered drugs and other substances
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
JPH01274830A (ja) * 1988-04-28 1989-11-02 Asahi Denka Kogyo Kk 安全で且つ高度な界面活性を有する脂質組成物
JPH03127731A (ja) * 1989-10-12 1991-05-30 Yakult Honsha Co Ltd ビタミンeの可溶化方法およびビタミンe製剤
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
EP2062574B1 (en) * 2006-09-08 2015-03-25 Kaneka Corporation Composition comprising reduced coenzyme q10 and lysolecithin
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
AU2015301952B2 (en) * 2014-08-09 2020-12-03 Avanti Polar Lipids, Inc. Oral composition for delivery of drugs and other substances

Also Published As

Publication number Publication date
KR102507657B1 (ko) 2023-03-08
KR20220070551A (ko) 2022-05-31
IL250394A0 (en) 2017-03-30
IL250394B (en) 2021-05-31
KR20170033442A (ko) 2017-03-24
AU2015301952B2 (en) 2020-12-03
CA2956960C (en) 2023-10-24
EP3177279B1 (en) 2025-06-04
CN107072967B (zh) 2021-01-12
WO2016025401A1 (en) 2016-02-18
US9872908B2 (en) 2018-01-23
CN107072967A (zh) 2017-08-18
US11510985B2 (en) 2022-11-29
DK3177279T3 (da) 2025-08-18
AU2015301952A1 (en) 2017-02-16
EP3177279A1 (en) 2017-06-14
JP6759203B2 (ja) 2020-09-23
CA2956960A1 (en) 2016-02-18
JP2017524036A (ja) 2017-08-24
US20180064813A1 (en) 2018-03-08
EP3177279A4 (en) 2018-04-18
US20200188518A1 (en) 2020-06-18
US20160166699A1 (en) 2016-06-16
US10463738B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
ES2654102T3 (es) Formulaciones líquidas para conjugado de C-CSF de acción prolongada
CA2948148C (en) Formulations of cyclophosphamide liquid concentrate
ES2904691T3 (es) Composiciones de taxanos orales y métodos
ES2880813T3 (es) Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas
ES2923929T3 (es) Formulación liposomal para uso en el tratamiento del cáncer
ES2837803T3 (es) Formulaciones de opioides
ES2981002T3 (es) Formulación farmacéutica
JP2019510048A (ja) 週1回又は隔週1回の投与に適したリラグルチドの粘弾性ゲル
ES2946600T3 (es) Formulaciones líquidas de daptomicina
ES2405743T3 (es) Composición farmacéutica que contiene furoato de mometasona
ES2687705T3 (es) Composición líquida que contiene un principio activo a base de taxano, proceso de producción de la misma y preparación medicinal líquida
ES2460730T3 (es) Formulaciones inyectables que contienen un complejo entre progesterona e hidroxipropil-betaciclodextrina
ES3033965T3 (en) Oral composition for delivery of drugs and other substances
ES2414557B1 (es) Composición acuosa de paracetamol para inyección
ES2747302T3 (es) Gel oftálmico de bimatoprost aplicable en gotas
AU2015202991B2 (en) Pharmaceutical composition
ES2362828T3 (es) Composición farmacéutica parenteral y su procedimiento de preparación.
ES2720731T3 (es) Medicamento para el tratamiento del vértigo de diferentes orígenes
ES2729328T3 (es) Formulaciones inyectables veterinarias de penetamato